Collins Helen Louise

CMO Helen Louise Collins sells 40,000 ELVN shares (61.5% of holdings) at $35.10; stock +32.6% in 30 days post-sale

Collins Helen Louise, Chief Medical Officer, sold 40,000 shares at $35.10 on 2026-03-25, reducing her holdings from 65,000 to 25,000 shares—a reduction of 61.5% relative to her pre-transaction position. The sale occurred at $35.10 while the stock currently trades at $38.83, and the stock has risen 32.6% in the 30 days following the sale. Her cross-ticker insider track record shows a 100.00% well-timed rate across 4 prior sells, but outcomes at Enliven specifically are mixed: of the 4 prior trades at ELVN, only 1 was measurable at the 90-day mark and showed a -8.0% return (well-timed). The company reported a net loss of $20,148,000 for its most recent full fiscal year, operating in an unprofitable state with a market cap of $2,322,049,764.98. The large stake reduction and post-sale price appreciation suggest the sale did not precede a material decline, and the unprofitable fundamentals context warrants monitoring whether further executive repositioning occurs.

CMO Helen Collins sold 40,000 ELVN shares for $1.2M at $30.07 avg, reducing stake by 61.5% to 25,000 shares post-transaction.

Collins Helen Louise, Chief Medical Officer, completed 2 separate sales totaling 40,000 shares for $1,202,637.98 on March 9–10, 2026, at a blended average price of $30.07, reducing her holdings from 65,000 to 25,000 shares (a 61.5% reduction in position). The sales occurred at the 52-week high of $30.70, with the stock up 9.3% over 30 days and 63.6% over 90 days. Enliven Therapeutics reported a net loss of $20,148,000 over its most recent full fiscal year; the substantial stake reduction by the CMO at peak valuation levels warrants attention against the company's unprofitable underlying fundamentals. Her prior open-market sale at this ticker on 2024-04-11 showed a 90-day decline of 8.0% following the trade, consistent with a 100% well-timed sell rate in her same-ticker history.

CMO Collins sold 45,000 ELVN shares ($1.2M) on 2026-02-17, reducing stake by 64.3%; stock down 3.3% in 30 days

Collins Helen Louise, Chief Medical Officer, sold 45,000 shares (45.0K shares) of Enliven Therapeutics at $26.17 on 2026-02-17 for $1,177,861.50 ($1.2M), reducing her holdings from 70,000 to 25,000 shares—a -64.3% reduction in her position. The sale occurred while the stock was down 3.3% over the prior 30 days and -11.1% from its 52-week high of $29.42, yet the insider's cross-ticker track record shows a 90d well-timed rate of 100.00%, with her prior ELVN sale on 2024-04-11 followed by -8.0% returns over 90 days. The company is unprofitable with net income of $-20,148,000.00 ($-20.1M), adding fundamental weakness to the technical signal. This substantial reduction in the CMO's stake—particularly from a leader responsible for clinical and medical strategy—warrants investor attention to whether this reflects reassessment of near-term medical or regulatory prospects.